4D Molecular Therapeutics, Inc. - Common Stock (FDMT)

4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to Regeneron's Eylea is set to begin in Q1 2025.

FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing anti-VEGF treatments.

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease.

FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and Phase 3 clinical trial preparations.

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.